CELZ Key Statistics, Chart & Performance
The current stock price of CELZ is 2.72 USD. In the past month the price decreased by -47.13%. In the past year, price increased by 2.06%.
CELZ Latest News, Press Relases and Analysis
CELZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About CELZ
Company Profile
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Company Info
CREATIVE MEDICAL TECHNOLOGY
211 E. Osborn Rd.
Phoenix ARIZONA US
Employees: 4
Phone: 14803992822
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What does CREATIVE MEDICAL TECHNOLOGY do?
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
What is the stock price of CREATIVE MEDICAL TECHNOLOGY today?
The current stock price of CELZ is 2.72 USD. The price decreased by -0.37% in the last trading session.
Does CREATIVE MEDICAL TECHNOLOGY pay dividends?
CELZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of CELZ stock?
CELZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for CREATIVE MEDICAL TECHNOLOGY?
CREATIVE MEDICAL TECHNOLOGY (CELZ) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for CREATIVE MEDICAL TECHNOLOGY?
CREATIVE MEDICAL TECHNOLOGY (CELZ) currently has 4 employees.
Can you provide the market cap for CREATIVE MEDICAL TECHNOLOGY?
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a market capitalization of 7.02M USD. This makes CELZ a Nano Cap stock.
CELZ Technical Analysis
CELZ Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CELZ. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability.
CELZ Financial Highlights
Over the last trailing twelve months CELZ reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS increased by 23.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.15% | ||
| ROE | -84.45% | ||
| Debt/Equity | 0 |
CELZ Forecast & Estimates
7 analysts have analysed CELZ and the average price target is 20.4 USD. This implies a price increase of 650% is expected in the next year compared to the current price of 2.72.
For the next year, analysts expect an EPS growth of 17.52% and a revenue growth -100% for CELZ